Literature DB >> 12210082

Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma.

Andrea Tannapfel1, Florian Sommerer, Markus Benicke, Lars Weinans, Alexander Katalinic, Felix Geissler, Dirk Uhlmann, Johann Hauss, Christian Wittekind.   

Abstract

The INK4a-ARF locus, located on chromosome 9p21, encodes two cell-cycle regulatory proteins, p16(INK4a) and p14(ARF), acting through the Rb-CDK4 and p53 pathways. To study the contribution of each pathway in the tumourigenesis of cholangiocarcinoma, the alterations of p14(ARF), p16(INK4a), p53, and pRb were analysed. After microdissection, DNAs from 51 cholangiocarcinomas were analysed by methylation-specific PCR (MSP), restriction-enzyme related polymerase chain reaction (RE-PCR), microsatellite analysis, mRNA expression, and DNA sequencing. Immunohistochemistry of p14(ARF), p16(INK4a), p53, and pRb was also performed. Promoter methylation of p14(ARF) was found in 13/51 cases (25%) and p16(INK4a) showed aberrant promoter methylation in 39/51 cases (76%) which correlated with loss of mRNA transcription. Two tumours (4%) had homozygous deletion of the INK4a-ARF locus. Specific mutations of both exons were not detected. p14(ARF) inactivation appeared in the context of an unmethylated p16(INK4a) promoter in eight of 13 cases (61%) of the carcinomas methylated at p14(ARF). Mutations of p53 were found in 19 of 51 tumours (37%), and four of them (21%) harboured p14(ARF) inactivation. The pRb protein was detected in 30/51 (59%) tumours examined. The absence of pRB protein did not correlate with any of the examined parameters. Alterations of the INK4a-ARF locus, pRB or p53 status could not be established as independent prognostic factors in these tumours. These findings indicate that the INK4a-ARF locus is frequently inactivated in cholangiocarcinoma of the liver and occurs independently of the status of p53 or pRb. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210082     DOI: 10.1002/path.1139

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  27 in total

1.  Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

Authors:  Michael R O'Dell; Jing Li Huang; Christa L Whitney-Miller; Vikram Deshpande; Paul Rothberg; Valerie Grose; Randall M Rossi; Andrew X Zhu; Hartmut Land; Nabeel Bardeesy; Aram F Hezel
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

Review 2.  Recent advances in the regulation of cholangiocarcinoma growth.

Authors:  Heather Francis; Gianfranco Alpini; Sharon DeMorrow
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

Review 3.  Genetic profiling of intrahepatic cholangiocarcinoma.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

Review 4.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

Review 5.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

Review 6.  Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs.

Authors:  Monique Stutes; Steven Tran; Sharon DeMorrow
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 7.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 8.  [Gallbladder and bile duct carcinoma. Biology and pathology].

Authors:  A Tannapfel; C Wittekind
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

Review 9.  Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets.

Authors:  Dalbir S Sandhu; Abdirashid M Shire; Lewis R Roberts
Journal:  Liver Int       Date:  2007-11-21       Impact factor: 5.828

10.  Aberrant DNA methylation of integrin alpha4: a potential novel role for metastasis of cholangiocarcinoma.

Authors:  Kyung-Ok Uhm; Jung Ok Lee; Yun Mi Lee; Eun Soo Lee; Hyeon Soo Kim; Sun-Hwa Park
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-05       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.